Patents Examined by Christopher M. Babic
  • Nanoparticles for targeting acid tumor microenvironments
    Patent number: 10012653
    Abstract: A composition is disclosed which is capable of being used for detection, comprising a noble metal nanoparticle. The inventive compositions exhibit little interaction with serum proteins while exhibiting pH-dependent adsorption onto live cell membranes. The nanoparticles of the claimed invention are capable of interacting with cell membranes, which in turn permits the advantages of nanoparticle bio-imaging to be extended to many pH dependent biological processes such as targeting acidic tumor microenvironment.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: July 3, 2018
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jie Zheng, Mengxiao Yu
  • Dosage compensating transgenes and cells
    Patent number: 10004765
    Abstract: Methods and compositions for reducing expression of genes on Chromosome 21 (“Chr 21”) by targeting an XIST transgene to the Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) gene or a Regulator of calcineurin 1 (RCAN1) gene, and cells and transgenic animals comprising an XIST transgene inserted into a DYRK1A or RCAN1 allele, e.g., cells and animals trisomic for human Chr 21 and mouse Chr 16.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 26, 2018
    Assignee: University of Massachusetts
    Inventors: Jeanne B. Lawrence, Jun Jiang, Lisa L. Hall
  • Fibrinogen preparations enriched in fibrinogen with an extended alpha chain
    Patent number: 10004787
    Abstract: The present invention relates to fibrinogen preparations enriched in ?-extended fibrinogen. Compositions comprising such preparations show improved clotting properties compared to preparations based on HMW Fib which typically contain no or only low amounts of ?-extended fibrinogen. In particular, clot formation time and the clot strength of a clot made by ?-extended fibrinogen are improved. In addition, plasmin-mediated degradation of ?-extended fibrinogen is reduced as compared to plasma derived fibrinogen.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: June 26, 2018
    Assignee: Mallinckrodt Pharma IP Trading D.A.C.
    Inventors: Joseph Grimbergen, Jacob Koopman, Abraham Bout
  • HIV-1 vaccine
    Patent number: 9988451
    Abstract: A method for inducing an immune response against HIV in a subject includes the step of preparing an HIV-1 gp120 envelope protein coding sequence particle having an N425K mutation, introducing the HIV-1 gp120 protein coding sequence particle having an N425K mutation into an expression construct using yeast homologous recombination, transfecting a cell with the expression construct, wherein the HIV-1 particle is secreted by the cell, and administering the secreted HIV-1 particle and a pharmaceutically acceptable carrier to the subject, wherein the secreted HIV-1 particle stimulates an immune response in the subject.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: June 5, 2018
    Assignee: Case Western Reserve University
    Inventors: Eric J. Arts, Annette Burkhouse
  • Transgenic mice having a human major histocompatibility complex (MHC) phenotype, experimental uses and applications
    Patent number: 9986721
    Abstract: The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+?2m°IA?°. The invention also relates to methods of using a transgenic mouse of the invention.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: June 5, 2018
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Claude Auriault, Véronique Pancre, Yu-Chun Lone, Anthony Pajot, François Lemonnier
  • Nuclease-mediated regulation of gene expression
    Patent number: 9957501
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: May 1, 2018
    Assignees: Sangamo Therapeutics, Inc., University Of Washington
    Inventors: Andreas Reik, John A. Stamatoyannopoulos, Jeff Vierstra
  • Vesicular stomatitis viruses
    Patent number: 9951117
    Abstract: This document provides methods and materials related to vesicular stomatitis viruses. For example, vesicular stomatitis viruses, nucleic acid molecules encoding VSV polypeptides, methods for making vesicular stomatitis viruses, and methods for using vesicular stomatitis viruses to treat cancer are provided.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: April 24, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Stephen James Russell, Shruthi Naik
  • Cell secreted proteins for the treatment of myocardial infarction
    Patent number: 9950016
    Abstract: The present invention relates to the use of secreted proteins from mesenchymal stem cells and other cells for the treatment of myocardial infarction. In particular, the invention provides compositions and methods based on secreted proteins from mesenchymal stem cells and the genes encoding them.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: April 24, 2018
    Assignee: NATIONAL UNIVERSITY OF IRELAND, GALWAY
    Inventors: Timothy O'Brien, Frank Barry, Claire Kavanagh
  • Gene vector
    Patent number: 9951328
    Abstract: A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: April 24, 2018
    Assignees: Fondazione Telethon, Ospedale San Raffaele S.r.l.
    Inventors: Alessandra Biffi, Bernhard Rudolf Gentner, Luigi Naldini
  • Mesenchymal stem cells and uses therefor
    Patent number: 9943547
    Abstract: Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: April 17, 2018
    Assignee: MESOBLAST INTERNATIONAL SÀRL
    Inventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
  • Treatment of ocular neovascularization using anti-VEGF proteins
    Patent number: 9943573
    Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: April 17, 2018
    Assignee: Avalanche Australia PTY Ltd.
    Inventors: Ian J. Constable, P. Elizabeth Rakoczy, Chooi-May Lai, Thomas W. Chalberg, Jr.
  • Pulsatile perfusion extraction method for non-embryonic pluripotent stem cells
    Patent number: 9944900
    Abstract: A method for extracting stem cells from a non-embryonic stem cell source, including providing a non-embryonic stem cell source including stem cells; perfusing the non-embryonic stem cell source with a pulsatile flow of a perfusion solution to produce a perfusate including stem cells and a perfused non-embryonic stem cell source; and isolating the stem cells from the perfusate to produce isolated stem cells, is provided. Also provided is a non-embryonic stem cell line derived from a non-embryonic stem cell obtained using the pulsatile perfusion extraction method.
    Type: Grant
    Filed: January 18, 2007
    Date of Patent: April 17, 2018
    Inventor: Fred Gage
  • Lipid encapsulating interfering RNA
    Patent number: 9926560
    Abstract: Rich tooling is provided for REST application development that integrates the exploration of a REST API, modeling of data types and the REST API, and the generation of artifacts using the modeled REST API and data types.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: March 27, 2018
    Assignee: Protiva Biotherapeutics, Inc.
    Inventors: Ian MacLachlan, Lorne R. Palmer, James Heyes
  • Drug carrier having L-DNA nanocage structure
    Patent number: 9919001
    Abstract: The present invention relates to a drug carrier having L-DNA nanocage structure prepared by using L-DNA, the mirror form of natural DNA, as a backbone. The drug carrier of the present invention has very superior cellular uptake efficiency and serum stability, so that it can be applied to deliver various drugs into cells usefully.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: March 20, 2018
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventor: Dae-Ro Ahn
  • Polycistronic expression system for bacteria
    Patent number: 9920324
    Abstract: The invention relates to polycistronic expression in gram-positive bacterium and in particular concerns polycistronic expression units comprising one or more gene endogenous to the gram-positive bacterium transcriptionally coupled to one or more genes exogenous to the bacterium.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: March 20, 2018
    Assignee: INTREXON ACTOBIOTICS NV
    Inventors: Klaas Vanden-Broucke, Karolien Van Huynegem, Lothar Steidler
  • Animal model and cell model developing amyotrophic lateral sclerosis
    Patent number: 9894890
    Abstract: Provided are a diagnosis marker, a diagnosis method, and a therapeutic agent suitable for diagnosing and treating amyotrophic lateral sclerosis (ALS). Also provided are an animal model and a cell model suitable for developing a therapeutic agent and a treatment method for ALS. The diagnosis method for ALS includes: an isolation step in which a nucleic acid is isolated from a specimen taken from a subject; a detection step in which bases expressed in a human chromosome 10 optineurin (OPTN) gene region are detected from the isolated nucleic acid; and a determination step in which it is determined whether or not the detected bases are mutated.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: February 20, 2018
    Assignee: HIROSHIMA UNIVERSITY
    Inventors: Hideshi Kawakami, Hirofumi Maruyama, Hiroyuki Morino
  • Method for producing induced pluripotent stem cells
    Patent number: 9890360
    Abstract: A method that includes bringing a nuclear reprogramming substance (DLX4 gene, OCT3/4 gene, and SOX2 gene) into contact with a cell and thereby producing iPS cells.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: February 13, 2018
    Assignees: GIFU UNIVERSITY, NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Kenichi Tezuka, Naritaka Tamaoki, Kazuki Iida, Tomoko Kawaguchi, Hitomi Aoki, Takahiro Kunisada, Toshiyuki Shibata, Naoki Goshima
  • Poxviral oncolytic vectors
    Patent number: 9884080
    Abstract: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: February 6, 2018
    Assignee: Transgene S.A.
    Inventors: Philippe Erbs, Johann Foloppe
  • TAFA4 compounds and uses thereof for treating pain
    Patent number: 9884088
    Abstract: The present invention relates to a method of using a TAFA4 protein or an agonist thereof for preventing, alleviating or treating pain in a subject. In one embodiment, the invention provides a method of treating pain in a subject by administering a TAFA4 protein or an agonist thereof to the subject. The TAFA4 can have the amino acid sequence of SEQ ID NO: 1 or 2 or a sequence having at least 90% sequence identity to SEQ ID NO: 1 or 2. The TAFA4 agonist can also be a peptide comprising 10 to 60 consecutive amino acid residues of SEQ ID NO: 1 or 2. Also described herein are pharmaceutical compositions, their preparation and uses as well as methods for preventing, alleviating or treating pain using such compounds and compositions.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: February 6, 2018
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'AIX-MARSEILLE
    Inventors: Aziz Moqrich, Marie-Claire Delfini, Annabelle Mantilleri
  • Restoring phosphorylation of a novel PINK1 substrate to treat parkinson's disease
    Patent number: 9879233
    Abstract: The present application relates to the field of Parkinson's disease (PD), particularly sporadic PD or PD associated with mutations in the mitochondrial kinase PINK1. A new substrate for this kinase, NdufA10, is identified herein. In Parkinson's disease, this protein is dephosphorylated, which is linked to a loss of mitochondrial membrane potential. It is shown that restoring or mimicking phosphorylation of NdufA10 restores the phenotypic defects associated with Parkinson's disease and is thus a new therapeutic paradigm.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: January 30, 2018
    Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Bart De Strooper, Patrik Verstreken, Vanessa Morais Epifânio